Table 1 Baseline characteristics

From: An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

 

UGT1A1 genotype group

Characteristics

Wild-type ( N =628)

Heterozygous ( N =539)

Homozygous ( N =145)

All ( N =1312)

Median age, years (IQR)

67 (61, 73)

66 (60, 73)

68 (61, 74)

67 (61, 73)

Gender, n (%)

Male

371 (59.1)

362 (67.2)

85 (58.6)

818 (62.3)

Female

257 (40.9)

177 (32.8)

60 (41.4)

494 (37.7)

Median BSA, m 2 (IQR)

1.52 (1.40, 1.66)

1.57 (1.44, 1.68)

1.54 (1.39, 1.67)

1.54 (1.42, 1.67)

UGT1A1 genetic profile, n (%)

 Wild-type group

    

 *1/*1

628 (100.0)

  

628 (47.9)

Heterozygous group

 

539 (100.0)

 

539 (41.1)

 *1/*6

 

308 (57.1)

 

308 (23.5)

 *1/*28

 

231 (42.9)

 

231 (17.6)

Homozygous group

  

145 (100.0)

145 (11.1)

 *6/*6

  

50 (34.5)

50 (3.8)

 *28/*28

  

23 (15.9)

23 (1.8)

 *6/*28

  

72 (49.7)

72 (5.5)

ECOG PS, n (%)

0

457 (72.8)

401 (74.4)

109 (75.2)

967 (73.7)

1

142 (22.6)

118 (21.9)

29 (20.0)

289 (22.0)

2

29 (4.6)

20 (3.7)

7 (4.8)

56 (4.3)

Treatment line, n (%)

First

138 (22.0)

125 (23.2)

21 (14.5)

284 (21.6)

Second or later

490 (78.0)

414 (76.8)

124 (85.5)

1028 (78.4)

Regimen, n (%)

FOLFIRI

395 (62.9)

349 (64.7)

96 (66.2)

840 (64.0)

Irinotecan+S-1

160 (25.5)

132 (24.5)

32 (22.1)

324 (24.7)

Irinotecan monotherapy

73 (11.6)

58 (10.8)

17 (11.7)

148 (11.3)

Molecular targeted agents, n (%)

None

236 (37.6)

209 (38.8)

51 (35.2)

496 (37.8)

Anti-VEGF mAb

274 (43.6)

223 (41.4)

64 (44.1)

561 (42.8)

Anti-EGFR mAb

118 (18.8)

107 (19.9)

30 (20.7)

255 (19.4)

Prior therapy, n (%)

Surgery

526 (83.8)

456 (84.6)

116 (80.0)

1098 (83.7)

Radiation

46 (7.3)

38 (7.1)

15 (10.3)

99 (7.5)

Chemotherapy

481 (76.6)

417 (77.4)

121 (83.4)

1019 (77.7)

Median WBC, 102 mm−3 (IQR)

53.5 (42.6, 66.8)

53.5 (42.0, 69.0)

52.0 (41.3, 63.5)

53.0 (42.0, 67.0)

Median ANC, 102 mm−3 (IQR)

31.3 (23.0, 41.7)

31.6 (23.3, 42.5)

31.0 (24.0, 41.0)

31.3 (23.1, 42.0)

Median platelet, 104 mm−3 (IQR)

18.7 (14.3, 24.4)

19.1 (14.6, 24.0)

18.3 (14.5, 23.5)

18.8 (14.5, 24.1)

Median total bilirubin level, mg dl−1 (IQR)

0.60 (0.40, 0.77)

0.60 (0.50, 0.87)

0.80 (0.60, 1.20)

0.60 (0.46. 0.80)

  1. Abbreviations: ANC=absolute neutrophil count; BSA=body surface area; ECOG PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; FOLFIRI=folinic acid, fluorouracil, and irinotecan; IQR=interquartile range; mAb=monoclonal antibody; UGT1A1=uridine diphosphate glucuronosyltransferase 1A1; VEGF=vascular endothelial growth factor; WBC=white blood cells.
Back to article page